PEN · Penumbra Inc
Price
Snapshot
50 fields · last close| Market Cap | $12.51B |
| P/E | 77.90 |
| Float | 38.17M |
| Beta | 0.71 |
| Volatility | 17.7% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 91 |
| Price | 317.74 |
| Change | +0.04% |
| Prev Close | 317.60 |
| Open | 319.19 |
| Day Low | 317.50 |
| Day High | 319.19 |
| Avg Vol | 0 |
| Avg $ Vol | $128.9M |
| 52W High | 362.41 |
| 52W Low | 221.26 |
| 52W Pos | 68.4% |
| From High | −12.33% |
| From Low | +43.60% |
| Max DD 1Y | −13.72% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.99% |
| SMA 50 | −1.14% |
| SMA 200 | −2.48% |
| RSI (14) | 38.9 |
| Vol 30D | 6.9% |
| Vol 90D | 7.5% |
| 1Y Range | 221–362 |
| Daily bars | 516 |
| Perf Week | −0.04% |
| Perf Month | −2.83% |
| Perf Quarter | +0.13% |
| Perf Half Y | −5.85% |
| Perf Year | +23.92% |
| Perf YTD | +2.69% |
| Prev Day | +0.04% |
| Clavix | A+ |
| Debt / Eq | 0.02 |
| Curr Ratio | 6.64 |
| Int Cover | — |
| FCF Margin | 14.4% |
| Rev Growth | +14.9% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 1 / 47 |
Clavix risk grade
regraded every trading dayPEN grades A+, 91 of 100. Steadiest on Price Stability (78), most exposed on Macro Resilience (68, steady). 4 of the 4 weighted dimensions sit above the Health Care median. Ranks 1 of 47 in Health Care by Clavix score.
How rough the ride is
| PEN | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.71 | 0.85 |
| Volatilityannualized | 17.7% | 21.2% |
| Max drawdown, past yearworst peak-to-trough fall | −13.7% | — |
| Typical daily movemedian absolute daily change | 0.39% | — |
| Days beyond ±3%of the last 252 sessions | 146% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| PEN | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.71 | 0.85 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate55% of 47 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| PEN | |
|---|---|
| 1 week | −0.0% |
| 1 month | −2.8% |
| Year to date | +2.7% |
| 1 year | +23.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| PEN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 16since 18 Jun |
| Average score0 most bearish, 100 most bullish | 61 |
| Bullish · bearisharticles above 60 · below 40 | 11 · 3 |
| Directionarticles whose tone is improving vs worsening | 11 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 47 Health Care names Clavix covers; the tick is the sector median.
Growth
| PEN | |
|---|---|
| Revenue growthyear over year | +14.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAn opinion piece argues that Penumbra's (PEN) portfolio expansion and international growth support holding the stock for now, while warning that rising costs, foreign exchange exposure, and margin pressure remain key risks.
An analyst piece outlines reasons to hold Penumbra (PEN) stock, citing portfolio expansion and international growth as positives while flagging rising costs, foreign exchange exposure, and margin pressure as risks. The article provides no specific earnings, product, or business development.
Equities researcher Zacks Research upgraded Penumbra (PEN) from a 'strong sell' rating to a 'hold' rating, and Weiss Ratings restated a 'hold (c)' rating on the stock.
Zacks Research changed its opinion on Penumbra, upgrading the stock from a "strong sell" rating to "hold" in a research note issued Monday. No reason for the change was given.
Kintayl Capital LP disclosed a new investment in Penumbra (PEN), buying 9,251 shares worth about $2.92 million during the second quarter, per its SEC 13F filing.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BAX | Baxter International Inc | B | $11.79B | — | 0.68 | Compare |
| DVA | DaVita Inc | B | $11.73B | 13.84 | 0.88 | Compare |
| BTSG | Brightspring Health Services Inc | B- | $11.23B | 30.70 | 1.89 | Compare |
| COO | Cooper Companies Inc | B- | $10.51B | 18.44 | 0.84 | Compare |
| ALGN | Align Technology Inc | B- | $10.49B | 25.35 | 1.74 | Compare |
| MOH | Molina Healthcare Inc | B | $10.48B | 22.21 | 0.73 | Compare |
| UHS | Universal Health Services Inc | A- | $10.41B | 6.82 | 1.12 | Compare |
| SOLV | Solventum Corp | B+ | $15.12B | 10.54 | 0.74 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.